Nass 2008 randomized 65 healthy older adults to 25 mg daily oral MK-677 vs placebo for 2 years and showed sustained increases in GH and IGF-1 to young-adult levels with significant lean-mass gain (+1.1 kg vs -0.5 kg placebo) and no serious adverse events. This is the best body-composition data for any oral GH secretagogue.
4 human studies · 8 animal studies
Lean mass +1.1 kg vs -0.5 kg placebo over 2 years (Nass 2008).
GH and IGF-1 sustained to young-adult range without tachyphylaxis.
Modest weight gain (~1.1 kg) and increased appetite — feature, not bug, in sarcopenic populations.
Insulin sensitivity decreased modestly — a real consideration in pre-diabetic users.
Top citations
Nass 2008 — 2-year RCT older adults
Chapman 1996 — Elderly GH/IGF-1 elevation
Our take
The strongest non-injectable GH secretagogue data we have. Watch fasting glucose; the appetite increase is the hidden tax.